Biology subjects

Miwa, S.

Publications and source records attributed to Miwa, S..

6 recordsLinked to original sources

bioRxiv2025

Human fibrosarcoma cells selected for very-high doxorubicin resistance, acquire trabectedin and eribulin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression

Doxorubicin is first-line chemotherapy for soft tissue sarcoma; however, the development of drug resistance limits its efficacy. The purpose of the present study was to select very-high doxorubicin-resistant (VHDR) HT1080 fibrosarcoma cells, determine cross-resistance to second-line chemotherapy drugs, determine maintenance of sensitivity to recombinant methioninase (r-METase) alone and in combination with doxorubicin, and measure the level of c-MYC expression. VHDR-HT1080 cells were generated by cultivating HT-1080 cells in a series of step-wise progressively higher concentrations of doxorubicin, ranging from 8 nM to 15 {micro}M, an 1875-fold increase, over a five-month period. The WST-8 reagent was used to assess cell viability. Four groups of in vitro drug-sensitivity tests were conducted, which involved both parental HT1080 and VHDR-HT1080 cells: 1) doxorubicin alone; 2) rMETase alone; 3) a combination of doxorubicin and rMETase; and 4) untreated control. The cross-resistance of VHDR-HT1080 cells to eribulin, trabectedin, gemcitabine and docetaxel was determined. The c-MYC levels in HT1080 and VHDR-HT1080 cells were measured using Western blotting. Doxorubicin had an IC50 of 3.3 {micro}M against HT1080 cells and 38.2 {micro}M against VHDR-HT1080 cells an 11.6-fold increase. The rMETase IC50 value for HT1080 was 0.75 U/ml and 0.59 U/ml for VHDR-HT1080. rMETase sensitized VHDR-HT1080 cells to doxorubicin. VHDR-HT1080 cells were cross-resistant to trabectedin 8.9-fold and cross-resistant to eribulin 1.87-fold compared to parental HT1080 cells. c-MYC expression was 8.4 times higher in VHDR-HT1080 cells compared to HT-1080 cells. The present results suggest rMETase may be used as a future clinical strategy to overcome super-doxorubicin resistance in soft tissue sarcoma.

cancer biology↗

bioRxiv2025

Repurposing Regulatory Toxicology Safety Data to Identify Potential Pro-Longevity Substances

The repurposing of existing biosafety datasets offers unique opportunities in biomedical research. Here, we demonstrate how pesticide toxicity data, which include long-term survival studies in mammalian models, can be harnessed to uncover potential drug candidates or drug targets that can improve survival. We show that these substances frequently affect mitochondrial bioenergetics and that they can improve animal healthspan.

cell biology↗

bioRxiv2024

Comparable anti-ageing efficacies of a multi-ingredient nutraceutical and a senolytic intervention in old mice

Single-ingredient dietary supplements have demonstrated some potential to extend lifespan and improve healthspan; however, the efficacy of defined multi-ingredient nutraceuticals remains underexplored. Senolytic interventions have been successful in reducing multi-morbidity, frailty, and cognitive decline in animal models and are seen as promising anti-ageing interventions in mammals. We compared the effects of a 12-ingredient nutraceutical on mice lifespan and healthspan markers with that of a high efficacy senolytic intervention consisting of a low dose of Navitoclax combined with the specific mitochondrial uncoupler BAM15. Both interventions were started at old age (20 months). The supplement was given daily until the end of the experiment (30 months of age), but the senolytic intervention consisted of two short (5 days each) rounds of treatment at 20 and 23 months of age. Despite late onset, both interventions increased median lifespan similarly by around 20% over controls. The senolytic intervention significantly reduced frailty progression and improved cognitive function after the second round of treatment, but without subsequent treatment, these effects appeared to wane at later ages. The multi-ingredient supplement tended to reduce frailty progression steadily with time, albeit not significant, and maintained cognitive function. Mechanistically, in vitro, there was no evidence of senolytic activity of the multi-ingredient nutraceutical as a whole nor of its individual ingredients. Continuous multi-ingredient dietary supplementation shows promise in achieving comparable anti-ageing efficacy as a senolytic intervention.

cell biology↗

bioRxiv2023

Mild uncoupling of mitochondria synergistically enhances senolytic specificity and sensitivity of BH3 mimetics

Anti-senescence interventions are exceptionally effective in alleviating a wide range of age-associated diseases and disabilities. However, the sensitivity and specificity of current senolytic interventions are limited. Mitochondrial dysfunction is an integral part of the senescent phenotype and we demonstrate that specific loss of complex I-linked coupled respiration and the inability to maintain mitochondrial membrane potential upon respiratory stimulation are early and persistent features in a cells progression towards senescence. We thus identify senescence-associated mitochondrial dysfunction as a targetable vulnerability of senescent cells and show that further decreasing mitochondrial membrane potential of senescent cells with a low concentration of a mitochondrial uncoupler synergistically enhances the in vitro senolytic efficacy of BH3 mimetic drugs, including Navitoclax, by up two orders of magnitude. Moreover, in an in vivo mouse model of radiation-induced premature ageing, we show that a short-term intervention combining the mitochondrial uncoupler BAM15 with Navitoclax at a dose two orders of magnitude lower than typically used reduces frailty and improves cognitive function for at least 8 months after irradiation. Therefore our study shows that compromised mitochondrial functional capacity is a specific vulnerability of senescent cells which can be targeted by mild uncoupling in vitro and in vivo.

cell biology↗

bioRxiv2021

Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice

Cancer survivors suffer from progressive frailty, multimorbidity and premature morbidity. We hypothesize that therapy-induced senescence and senescence progression via bystander effects is a significant cause of this premature ageing phenotype. Accordingly, the study addresses the question whether a short anti-senescence intervention is able to block progression of radiation-induced frailty and disability in a pre-clinical setting. Male mice were sub-lethally irradiated at 5 months of age and treated (or not) with either a senolytic drug (Navitoclax or dasatinib + quercetin) for 10 days or with the senostatic metformin for 10 weeks. Follow up was for one year. Treatments commencing within a month after irradiation effectively reduced frailty progression (p<0.05) and improved muscle (p<0.01) and liver (p<0.05) function as well as short-term memory (p<0.05) until advanced age with no need for repeated interventions. Senolytic interventions that started late, after radiation-induced premature frailty was manifest, still had beneficial effects on frailty (p<0.05) and short-term memory (p<0.05). Metformin was similarly effective as senolytics. At therapeutically achievable concentrations metformin acted as a senostatic neither via inhibition of mitochondrial complex I, nor via improvement of mitophagy or mitochondrial function, but by reducing non-mitochondrial ROS production via NOX4 inhibition in senescent cells. Our study suggests that the progression of adverse long-term health and quality-of-life effects of radiation exposure, as experienced by cancer survivors, might be rescued by short-term adjuvant anti-senescence interventions.

cancer biology↗

bioRxiv2020

Pex11 β knockdown decreases peroxisome abundance and reverses the inhibitory effect of palmitate on pancreatic beta-cell function.

AimsReactive oxygen species generated by the peroxisomes and mitochondria contribute to lipotoxicity in pancreatic beta-cells. Through targeted Pex11{beta} knockdown and peroxisome depletion, our aim was to investigate the specific contribution of peroxisomes to palmitate mediated pancreatic beta-cell dysfunction. MethodsMIN6 cells were transfected with probes targeted against Pex11{beta}, a regulator of peroxisome abundance, or with scrambled control probes. Peroxisome abundance was measured by PMP-70 protein expression. 48hrs post transfection, cells were incubated with or without 250M palmitate for a further 48hrs before measurement of reactive oxygen species, mitochondrial respiratory function, and glucose stimulated insulin secretion. ResultsPex11{beta} knockdown decreased target gene expression by more than 80% compared with the scrambled control (P<0.001), leading to decreased PMP-70 expression (p<0.01). Pex11{beta} knockdown decreased palmitate mediated generation of reactive oxygen species (P<0.001), but with no effect on mitochondrial respiratory function. At 25mM glucose, palmitate treatment decreased insulin secretion in the control cells (2.54{+/-}0.25 vs 7.07{+/-}0.83 [mean{+/-}SEM] ng/hr/g protein; P<0.001), with a similar pattern in the Pex11{beta} knockdown cells. However, in the presence of palmitate, insulin secretion was significantly higher in the Pex11{beta} knockdown versus control cells (4.04{+/-}0.46 vs 2.54{+/-}0.25 ng/hr/g protein; p<0.05). ConclusionPex11{beta} knockdown decreased peroxisome abundance, decreased palmitate mediated ROS generation, and reversed the inhibitory effect of palmitate on insulin secretion. These findings highlight a specific and independent role for peroxisomes in pancreatic beta-cell lipotoxicity.

cell biology↗